Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Twist Bioscience Corporation, Alnylam Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc.

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Twist Bioscience Corporation, Alnylam Pharmaceuticals, Inc. Stock News

As of September 21, 2026, Twist Bioscience Corporation had a $10.4 billion market capitalization, compared to the Biotechnology median of $269.5 million. Twist Bioscience Corporation’s stock is up 422.8% in 2026, up 23.1% in the previous five trading days and up 493.31% in the past year.

Currently, Twist Bioscience Corporation does not have a price-earnings ratio. Twist Bioscience Corporation’s trailing 12-month revenue is $431.8 million with a -31.7% net profit margin. Year-over-year quarterly sales growth most recently was 23.2%. Analysts expect adjusted earnings to reach $-0.600 per share for the current fiscal year. Twist Bioscience Corporation does not currently pay a dividend.

As of September 21, 2026, Alnylam Pharmaceuticals, Inc. had a $32.7 billion market cap, putting it in the 90th percentile of all stocks. Alnylam Pharmaceuticals, Inc.’s stock is down 38.6% in 2026, down 2.3% in the previous five trading days and down 45.97% in the past year.

Currently, Alnylam Pharmaceuticals, Inc.’s price-earnings ratio is 43.5. Alnylam Pharmaceuticals, Inc.’s trailing 12-month revenue is $4.8 billion with a 16.1% net profit margin. Year-over-year quarterly sales growth most recently was 66.8%. Analysts expect adjusted earnings to reach $8.845 per share for the current fiscal year. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Twist Bioscience Corporation	TWST	D
Alnylam Pharmaceuticals, Inc.	ALNY	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Twist Bioscience Corporation has a Quality Score of 31, which is Weak. Alnylam Pharmaceuticals, Inc. has a Quality Score of 86, which is Very Strong.

The Quality Grade Winner: Alnylam Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Alnylam Pharmaceuticals, Inc. has a better overall quality grade than Twist Bioscience Corporation. For investors who are looking for companies with higher quality than others in the same industry, Alnylam Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Twist Bioscience Corporation	TWST	A
Alnylam Pharmaceuticals, Inc.	ALNY	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Twist Bioscience Corporation has a Momentum Score of 99, which is Very Strong. Alnylam Pharmaceuticals, Inc. has a Momentum Score of 15, which is Very Weak.

The Momentum Grade Winner: Twist Bioscience Corporation

As you can clearly see from the Momentum Grade breakdown above, Twist Bioscience Corporation is considered to have stronger momentum compared to Alnylam Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Twist Bioscience Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Twist Bioscience Corporation	TWST	D
Alnylam Pharmaceuticals, Inc.	ALNY	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Twist Bioscience Corporation has a Earnings Estimate Score of 38, which is Negative. Alnylam Pharmaceuticals, Inc. has a Earnings Estimate Score of 29, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Twist Bioscience Corporation, Alnylam Pharmaceuticals or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Twist Bioscience Corporation, Alnylam Pharmaceuticals or Inc. is the better investment when it comes to estimate revisions.

Other Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc. Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Twist Bioscience Corporation, Alnylam Pharmaceuticals or Inc. Stock?

Overall, Twist Bioscience Corporation stock has a Momentum Score of 99, Estimate Revisions Score of 38 and Quality Score of 31.

Alnylam Pharmaceuticals, Inc. stock has a Momentum Score of 15, Estimate Revisions Score of 29 and Quality Score of 86.

Comparing Twist Bioscience Corporation, Alnylam Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.